E-64

E-64

SCHEMBL7087294

CC(C)CC(NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCCCNC(=N)N

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 14/20 0.74
CTSB P07858 4/20 0.74
CTSL P07711 4/20 0.74
CTSK P43235 2/20 0.74
CAPN9 O14815 2/20 0.74
MAPK1 P28482 2/20 0.74
LMNA P02545 2/20 0.74
CTSH P09668 1/20 0.74
CTSS P25774 1/20 0.74
CTSC P53634 1/20 0.74
CYP3A4 P08684 1/20 0.74
TSHR P16473 1/20 0.74
CYP2C19 P33261 1/20 0.74
USP2 O75604 1/20 0.74
MAPT P10636 1/20 0.74
BLM P54132 1/20 0.74
CTSG P08311 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
E-64 SCHEMBL13283063 1.00 CAPN1 (0.74) CAPN1CTSBCTSLCTSKCAPN9
E-64 SCHEMBL23132676 1.00 CAPN1 (0.74) CAPN1CTSBCTSLCTSKCAPN9
E-64 SCHEMBL4740187 1.00 CAPN1 (0.74) CAPN1CTSBCTSLCTSKCAPN9
E-64 SCHEMBL13523481 1.00 CAPN1 (0.74) CAPN1CTSBCTSLCTSKCAPN9
E-64 SCHEMBL16452857 1.00 CAPN1 (0.74) CAPN1CTSBCTSLCTSKCAPN9
E-64 SCHEMBL32663599 0.99 CAPN1 (0.73) CAPN1CTSBCTSLCTSKCAPN9
SCHEMBL11067480 0.88 CAPN1 (0.74) CAPN1CTSBCTSLCTSKCAPN9
Agmatine SCHEMBL18784085 0.88 CAPN1 (0.59) CAPN1CTSBCTSLCTSKCAPN9
SCHEMBL11184932 0.87 CAPN1 (0.72) CAPN1CTSBCTSLCTSKCAPN9
SCHEMBL11188762 0.87 CAPN1 (0.72) CAPN1CTSBCTSLCTSKCAPN9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed